CEPI awards up to US$23.4 million to Valneva for late-stage development of a single-dose Chikungunya vaccine

    NEXT STORY
    Curetis to Present at Solebury Trout European Biotech Investor Day in NYC
    PREV STORY
    Roxadustat China Phase 3 Trial for Treatment of Anemia in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine (NEJM)
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    NeuBase Therapeutics Designates Industry Leaders to Board of Directors 

    author_avatar
    NASDAQ Market News

    THE ELSAH PROJECT PUSHES THE LIMITS OF WEARABLES

    author_avatar
    NASDAQ Market News

    Medibio Clinical Study Shows Over 20% Improvement to Current Diagnostic Standard

    Highlights: Global 230 patient (8 sites) study confirms Medibio’s Depression Diagnostic Aide (DX04)With 70% ...

    author_avatar
    NASDAQ Market News